The co-treatment of apoA-I:CIGB-258 reduced the AO and DHE fluorescence in a dose-dependent manner of CIGB-258, especially the 1:1 molar ratio injected group showed the lowest AO and DHE fluorescence, which was 77% (p < 0.001), and 70% (p < 0.001), less than those observed in CML+PBS injected group, respectively. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.